Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2024 | CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma

Enrique Grande • 25 Jan 2024
GU Cancers 2024
Genitourinary Cancer Neuroendocrine Tumor Antibodies Atezolizumab Cabozantinib Checkpoint Inhibitors
CABATEN

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses results from the Phase II CABATEN trial (NCT04400474) of cabozantinib and atezolizumab in patients with advanced and refractory adrenocortical carcinoma (ACC), who had progressed on prior chemotherapy and/or mitotane. Promising activity was reported in patients receiving the investigational therapy and safety was consistent with previous studies. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Enrique Grande

Current care and biomarker needs in first-line metastatic urothelial cancer
1:47
Current care and biomarker needs in first-line metastatic urothelial cancer
Enrique Grande • 19 Oct 2025
Novel strategies for the management of metastatic urothelial cancer
1:28
Novel strategies for the management of metastatic urothelial cancer
Enrique Grande • 19 Oct 2025
Novel ADCs for bladder cancer beyond enfortumab vedotin
1:57
Novel ADCs for bladder cancer beyond enfortumab vedotin
Enrique Grande • 19 Oct 2025
Evolving standards in first-line metastatic urothelial cancer
1:11
Evolving standards in first-line metastatic urothelial cancer
Enrique Grande • 19 Oct 2025

Related Videos

Prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors
1:40
Prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors
Rocio Garcia-Carbonero • 2 Jul 2026
DLL3: a promising target in neuroendocrine carcinomas
2:44
DLL3: a promising target in neuroendocrine carcinomas
Rocio Garcia-Carbonero • 2 Jul 2026
Current and emerging strategies for targeting NETs
7:13
Current and emerging strategies for targeting NETs
Rocio Garcia-Carbonero • 2 Jul 2026
Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals